PR Newswire

Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications

HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase ...

AbbVie: Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 ... - FinanzNachrichten.de

HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported statisticall ...
MarketScreener

Allergan Aesthetics Announces Results from HARMONY IN DIVERSITY and HALO Phase 4 Studies of Aesthetic Treatment in Adults on GLP-1 Medications

Allergan Aesthetics, an AbbVie company, announced results from HARMONY IN DIVERSITY and HALO, two Phase 4 studies of aesthetic treatment in adults on glucagon-like peptide-1 (GLP-1) medications.
MarketersMEDIA Newsroom

Sucré Expands Into Medical Aesthetics With Sucré Medical in Calgary and Okotoks

Growing Alberta beauty and wellness brand expands into medical aesthetics, injectable treatments and women’s health services at its Crowfoot and Okotoks locations ...